Transcriptomics

Dataset Information

6

Expression data from MTDH knockdown in the Hec50co endometrial cancer cell line


ABSTRACT: Understanding the molecular underpinnings of chemoresistance is vital to design therapies to restore chemosensitivity. In particular, metadherin (MTDH) has been demonstrated to have a critical role in chemoresistance. Over-expression of MTDH has recently been implicated in poor clinical outcome in breast cancer, neroblastoma, hepatocellular carcinoma and prostate cancer. In this present study, we focused on the therapeutic benefit of MTDH depletion to restore sensitivity to cell death mediated by a combinatorial therapy of tumor necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL), which promotes death of cancerous cells of the human reproductive tract, and histone deacetylase (HDAC) inhibitors, which have been shown to increase sensitivity of cancer cells to TRAIL-induced apoptosis. Our data indicate that depletion of MTDH in endometrial cancer cells results in sensitization of cells that were previously resistant to cell death mediated by combinatorial treatment with TRAIL and HDAC inhibitor LBH589. MTDH was found to be involved in G2/M checkpoint regulation in response to LBH589 alone or LBH589 in combination with TRAIL, suggesting that MTDH functions at the cell cycle checkpoint to accomplish resistance.Using microarray technology, we identified 57 downstream target genes of MTDH, including Calbindin 1 and Galectin 1, which may contribute to MTDH-mediated resistance to combinatorial TRAIL and HDAC inhibitor targeted therapy. Inhibition of PDK1,AKT phosphorylation and increase Bim expression and XIAP degradation may result in sensitivity to cell death induction in MTDH depleted Hec50co cells by TRAIL and LBH 589 combination treatment. These findings indicate that depletion of MTDH is a potentially novel avenue for effective cancer therapy. The microarray was performed on three biological triplicates as well as three experimental triplictes of stable knockdown and control cells. MTDH was knocked down using a shRNA.

REANALYSED by: E-GEOD-26134

ORGANISM(S): Homo sapiens  

SUBMITTER: Kimberly Leslie   Xiangbing Meng  Pavla Brachova 

PROVIDER: E-GEOD-26134 | ArrayExpress | 2010-12-17

SECONDARY ACCESSION(S): GSE26134PRJNA135381

REPOSITORIES: GEO, ArrayExpress

altmetric image

Publications

Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.

Meng Xiangbing X   Brachova Pavla P   Yang Shujie S   Xiong Zhi Z   Zhang Yuping Y   Thiel Kristina W KW   Leslie Kimberly K KK  

PloS one 20110608 6


Understanding the molecular underpinnings of chemoresistance is vital to design therapies to restore chemosensitivity. In particular, metadherin (MTDH) has been demonstrated to have a critical role in chemoresistance. Over-expression of MTDH correlates with poor clinical outcome in breast cancer, neuroblastoma, hepatocellular carcinoma and prostate cancer. MTDH is also highly expressed in advanced endometrial cancers, a disease for which new therapies are urgently needed. In this present study,  ...[more]

Similar Datasets

2011-05-01 | E-GEOD-27828 | ArrayExpress
2015-08-12 | E-GEOD-26134 | ExpressionAtlas
2011-05-01 | GSE27828 | GEO
2010-12-17 | GSE26134 | GEO
2011-07-12 | E-GEOD-30588 | ArrayExpress
2012-04-14 | E-GEOD-36444 | ArrayExpress
2016-04-04 | E-GEOD-67249 | ArrayExpress
2012-04-17 | E-GEOD-26807 | ArrayExpress
2014-10-08 | E-GEOD-55050 | ArrayExpress
2016-06-15 | E-GEOD-38745 | ArrayExpress